Anagrelide for the treatment of essential thrombocythemia

Anagrelide (Anagrelide) is a specific platelet production inhibitor used to treat essential thrombocythemia (ET) and belongs to the class of phosphodiesterase Ⅲ (PDEⅢ) inhibitory drugs. It is unique in that it reduces platelet production primarily by inhibiting the maturation process of megakaryocytes without significantly affecting the number of red blood cells or white blood cells. Essential thrombocythemia is a myeloproliferative disease. The core problem is an abnormal increase in platelets, which leads to an increase in blood viscosity, thereby increasing the risk of complications such as thrombosis, cerebral infarction or myocardial infarction.

From a pharmacological mechanism, anagrelide can specifically inhibit the cyclic adenosine monophosphate degrading enzyme in megakaryocytes, thereby increasing intracellular cAMP levels and blocking their differentiation into mature platelets. In addition, it mildly inhibits platelet aggregation and vasoconstriction, indirectly helping to prevent thrombosis. Unlike traditional myelosuppressive drugs (such as hydroxyurea or interferon), anagrelide has less overall inhibitory effect on the bone marrow and hematopoietic system, so the side effects are relatively mild, and it is more suitable for long-term maintenance treatment or use in elderly patients.

Overseas studies have shown that anagrelide can significantly reduce platelet counts within 2 to 3 weeks and maintain stable control; in most patients, platelets can be maintained within a safe range, thereby significantly reducing the risk of thrombotic events. Its efficacy is particularly outstanding in high-risk ET patients, especially for patients whose previous use of hydroxyurea has had poor efficacy or intolerance. Anagrelide provides a reliable alternative. The convenience of oral administration also makes patient compliance higher.

The dosage of anagrelide must be gradually adjusted under the guidance of a doctor. The initial dose is usually low and gradually increased based on platelet response and adverse effects. Some patients may experience mild palpitations, headache, fatigue, or gastrointestinal discomfort early in treatment, which is usually transient.

Reference materials:https://go.drugbank.com/drugs/DB00261